Pancreatic Ductal Adenocarcinoma Pipeline Review H2 2015

1. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Nov-2015 No. of pages: 162 Single User License: US $2000 Browse more Reports on Cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: AbbVie Inc., BerGenBio AS, Clovis Oncology, Inc., Coare Biotechnology, Inc., FibroGen, Inc., Gilead Sciences, Inc., Immodulon Therapeutics Ltd., Immunomedics, Inc., Incuron, LLC, Merck & Co., Inc., Nerviano Medical Sciences S.r.l., OncoMed Pharmaceuticals, Inc., SillajenBiotherapeutics, Tara Immuno-Oncology Therapeutics LLC and Tokai Pharmaceuticals, Inc. Drugs Profile Discussed in this Research: BGB-324, CBL-0137, CBT-1111, CBT-3112, demcizumab, FG-3019, galeterone, Hu-5F9G4, ibrutinib, idelalisib, IMM-101, ipafricept, JX-929, MK-0752, MK-8628, momelotinibdihydrochloride, MRK-003, NMSP-715, Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma, PSL-001, rucaparib phosphate, sacituzumab, SBP-101, siG12D-LODER, Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer, Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma and vantictumab ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 Scope For Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441